
Dapagliflozin Improves Heart Structure in HFpEF Patients with Type 2 Diabetes:Study
A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, significantly reduces myocardial fibrosis and enhances cardiac structure, exercise capacity, and metabolic …